Apellis Pharmaceuticals, Inc (APLS)

Etorro trading 970x250

About Apellis Pharmaceuticals, Inc

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

Apellis Pharmaceuticals, Inc News and around…

Latest news about Apellis Pharmaceuticals, Inc (APLS) common stock and company :

Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)
21 Oct, 2021 Yahoo! Finance

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds?
18 Oct, 2021 Yahoo! Finance

In this article we are going to use hedge fund sentiment as a tool and determine whether Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, […]

Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug
18 Oct, 2021 Yahoo! Finance

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
15 Oct, 2021 Yahoo! Finance

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of Aspaveli® (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who are anemic after treatment with a

Cramer Likes DraftKings, Skyworks, And These Automakers
07 Oct, 2021 FinancialContent

On CNBC's "Mad Money Lightning Round," Jim Cramer said he was a buyer of DraftKings Inc (NASDAQ: DKNG). He believes the ...

Is Good News Enough for You to Buy NGM on the Dip?
06 Oct, 2021 FinancialContent

A drop in the overall market provides an opportunity for investors to pounce.

Analysts Forecast 19% Upside For ESML
04 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $47.27 per unit.

Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
30 Sep, 2021 FinancialContent
4 Midsize Biotech Stocks That Have Breakout Potential
22 Sep, 2021 Yahoo! Finance

It’s been a tough year for small- and mid-cap biotech stocks. We looked at four names in the mid-cap biotech space that analysts love.

Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference
20 Sep, 2021 FinancialContent
Better Pharmaceutical Stock: Apellis or Novartis?
15 Sep, 2021 FinancialContent

The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments.

First Week of APLS January 2024 Options Trading
15 Sep, 2021 FinancialContent

Investors in Apellis Pharmaceuticals Inc (APLS) saw new options begin trading this week, for the January 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 856 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Interesting APLS Put And Call Options For November 19th
14 Sep, 2021 FinancialContent

Investors in Apellis Pharmaceuticals Inc (APLS) saw new options begin trading today, for the November 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APLS options chain for the new November 19th contracts and identified one put and one call contract of particular interest.

Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
13 Sep, 2021 FinancialContent

Raymond James has upgradedNGM Biopharmaceuticals Inc(NASDAQ: NGM) toStrong Buy from Outperformwith a price ...

Apellis (APLS) Down on Mixed Data From Studies on GA Candidate
13 Sep, 2021 Yahoo! Finance

Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.

60 Biggest Movers From Friday
13 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported ...

Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher
10 Sep, 2021 FinancialContent

Toward the end of trading Friday, the Dow traded down 0.31% to 34,772.74 while the NASDAQ fell 0.27% to 15,207.42. The S&P also ...

What 11 Analyst Ratings Have To Say About Apellis Pharmaceuticals
10 Sep, 2021 FinancialContent

Over the past 3 months, 11 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are ...

8 Health Care Stocks With Unusual Options Alerts In Today's Session
10 Sep, 2021 FinancialContent

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the ...

APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today
10 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results. The post APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Dow Eyes Fifth-Straight Skid, Another Weekly Drop
10 Sep, 2021 FinancialContent

The Dow Jones Industrial Index is giving up its earlier gains, last seen down 149 points, as investors fail to shake off the economic uncertainty that's blanketed the holiday-shortened week.

Why Apellis Pharmaceutical Shares Are Plunging Today
10 Sep, 2021 FinancialContent

Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Fridayafter the company announced itsPhase 3 DERBY study in ...

12 Health Care Stocks Moving In Friday's Intraday Session
10 Sep, 2021 FinancialContent

Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC ...

Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge
10 Sep, 2021 FinancialContent

Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, ...

41 Stocks Moving In Friday's Mid-Day Session
10 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its ...

Here's Why Iveric Bio Stock Is Rocketing Higher Today
10 Sep, 2021 FinancialContent

Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.

ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio
10 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today. The post ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Here's Why Apellis Pharmaceuticals Is Getting Hammered Today
10 Sep, 2021 FinancialContent

Conflicting clinical trial results for the company's lead candidate are to blame.

Why IVERIC Bio Shares Are Soaring Today
10 Sep, 2021 FinancialContent

IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Fridayafter Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported ...

Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views
10 Sep, 2021 FinancialContent

Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also ...

Apellis Pharmaceuticals, Inc (APLS) is a NASDAQ Common Stock listed in , ,

970x250